Capricor Therapeutics IncNASDAQ:CAPR
- LAST PRICE3.7300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots3.2500/ 1
- Ask / Lots4.1700/ 3
- Open / Previous Close0.0000 / 3.7300
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CAPR |
|---|---|---|
| 09:32 ET | 2228 | 3.61 |
| 09:34 ET | 100 | 3.62 |
| 09:41 ET | 800 | 3.66 |
| 09:45 ET | 200 | 3.67 |
| 09:52 ET | 600 | 3.68 |
| 09:56 ET | 6325 | 3.65 |
| 10:01 ET | 100 | 3.67 |
| 10:06 ET | 490 | 3.6415 |
| 10:15 ET | 1405 | 3.69 |
| 10:19 ET | 100 | 3.69 |
| 10:24 ET | 438 | 3.72 |
| 10:32 ET | 2000 | 3.7338 |
| 10:33 ET | 1200 | 3.7246 |
| 10:35 ET | 2333 | 3.78 |
| 10:37 ET | 200 | 3.74 |
| 10:39 ET | 100 | 3.77 |
| 10:44 ET | 600 | 3.77 |
| 10:46 ET | 313 | 3.74 |
| 10:55 ET | 1000 | 3.7225 |
| 10:57 ET | 100 | 3.75 |
| 11:00 ET | 100 | 3.73 |
| 11:02 ET | 511 | 3.75 |
| 11:18 ET | 100 | 3.77 |
| 11:31 ET | 200 | 3.73 |
| 11:47 ET | 100 | 3.71 |
| 11:54 ET | 100 | 3.75 |
| 11:58 ET | 100 | 3.75 |
| 12:00 ET | 100 | 3.75 |
| 12:20 ET | 800 | 3.765 |
| 12:27 ET | 800 | 3.8 |
| 12:39 ET | 5455 | 3.77 |
| 12:43 ET | 200 | 3.75 |
| 12:50 ET | 800 | 3.7305 |
| 12:57 ET | 100 | 3.73 |
| 01:08 ET | 300 | 3.755 |
| 01:12 ET | 300 | 3.73 |
| 01:14 ET | 3400 | 3.74 |
| 01:15 ET | 2860 | 3.785 |
| 01:17 ET | 1300 | 3.81 |
| 01:19 ET | 2000 | 3.77 |
| 01:21 ET | 3666 | 3.77 |
| 01:24 ET | 3500 | 3.75 |
| 01:26 ET | 7328 | 3.77 |
| 01:28 ET | 1320 | 3.74 |
| 01:30 ET | 5000 | 3.745 |
| 01:37 ET | 600 | 3.7564 |
| 01:44 ET | 10298 | 3.69 |
| 01:53 ET | 100 | 3.75 |
| 02:00 ET | 400 | 3.71 |
| 02:08 ET | 100 | 3.745 |
| 02:13 ET | 500 | 3.77 |
| 02:15 ET | 100 | 3.73 |
| 02:18 ET | 180 | 3.73 |
| 02:29 ET | 100 | 3.73 |
| 02:44 ET | 100 | 3.73 |
| 02:47 ET | 500 | 3.77 |
| 03:21 ET | 100 | 3.69 |
| 03:27 ET | 120 | 3.715 |
| 03:30 ET | 200 | 3.69 |
| 03:32 ET | 300 | 3.69 |
| 03:43 ET | 679 | 3.71 |
| 03:48 ET | 5199 | 3.715 |
| 03:50 ET | 100 | 3.715 |
| 03:52 ET | 953 | 3.73 |
| 03:54 ET | 954 | 3.73 |
| 03:57 ET | 300 | 3.7 |
| 03:59 ET | 2816 | 3.73 |
Jun 27, 2022
Capricor Therapeutics Says CAP-1002 Study Data Shows 'Statistically Significant Improvements' to Treat Muscular Dystrophy, from 7:59AM ET on Monday Jun 27, 2022 by MT Newswires
7:59AM ET on Monday Jun 27, 2022 by MT NewswiresBRIEF-Capricor Therapeutics Announces Statistically Significant Clinical Benefits In Skeletal Muscle Function In Non-Ambulant Duchenne Muscular Dystrophy Patients Treated With Cap-1002 In Hope-2 Open Label Extension Study, from 7:07AM ET on Monday Jun 27, 2022 by Thomson Reuters
7:07AM ET on Monday Jun 27, 2022 by Thomson ReutersCapricor Therapeutics Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with CAP-1002 in HOPE-2 Open Label Extension Study, from 7:00AM ET on Monday Jun 27, 2022 by GlobeNewswire
7:00AM ET on Monday Jun 27, 2022 by GlobeNewswire
Jun 17, 2022
BRIEF-Capricor Therapeutics To Present One-Year Efficacy Results From Its Ongoing Hope-2 Open Label Extension Study At 2022 Parent Project Muscular Dystrophy Annual Conference, from 9:01AM ET on Friday Jun 17, 2022 by Thomson Reuters
9:01AM ET on Friday Jun 17, 2022 by Thomson ReutersCapricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022 Parent Project Muscular Dystrophy Annual Conference, from 9:00AM ET on Friday Jun 17, 2022 by GlobeNewswire
9:00AM ET on Friday Jun 17, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Capricor Therapeutics Inc | 90.7M | -3.9x | --- |
Candel Therapeutics Inc | 91.0M | -2.5x | --- |
Xilio Therapeutics Inc | 91.2M | -1.1x | --- |
Anixa Biosciences Inc | 91.4M | -5.8x | --- |
Eliem Therapeutics Inc | 91.9M | -1.8x | --- |
Galectin Therapeutics Inc | 87.9M | -2.6x | --- |
Company Information
Capricor Therapeutics, Inc. is a biotechnology company that is focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. The Company consists of cell therapy program, including CAP-1002 for Duchenne Muscular Dystrophy program and CAP-1002 with CAP-1002 for coronavirus (COVID-19). The Company’s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology therapeutic platform. The Company is focused on developing exosomes capable of delivering nucleic acids, including messenger RNA (mRNA) as well as proteins, to treat or prevent a range of diseases. CAP-1002 cell therapy programs initiated Pivotal Phase III, HOPE-3.
Contact Information
- Headquarters
- 2ND FLOOR, 8840 WILSHIRE BLVDBEVERLY HILLS, CA, United States 90211
- Phone
- 310-358-3200
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Frank Litvack
- President, Chief Executive Officer, Director
- Linda Marban
- Chief Financial Officer, Principal Accounting Officer
- Anthony Bergmann
- Executive Vice President, General Counsel
- Karen Krasney
- Independent Director
- Earl Collier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $90.7M |
|---|---|
Revenue (TTM) | $204.1K |
Shares Outstanding | 24.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 5.12 |
EPS | $-0.96 |
Book Value | $1.30 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 444.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -11,416.42% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
